Medical and Pharmaceutical Krystal Biotech co-founder makes Forbes 250 innovators list News comes after the company attained RMAT designation from the FDA for its lung cancer drug Rowan DunneFebruary 11, 2026
Medical and Pharmaceutical Krystal Biotech reports success with inhalable lung cancer drug in early-stage trial KB707 demonstrated a 27% objective response rate and 73% disease control rate Rowan DunneDecember 19, 2024